CellRapeutics™ In Vivo CAR-M Cell Engineering Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The Prospect of In Vivo CAR-M Cell Engineering Service

Macrophages (M cells) are the most prevalent innate immune cells in the TME of solid tumors, accounting for up to 50%. Inspired by CAR-T and CAR-NK, CAR-M cells are being widely developed due to the capacity of CARM cells to invade solid tumors and traverse to inhibit TME. They are generally engineered utilizing viral vectors ex vivo, which has been limited by obstacles such as complex ex vivo procedures, and expensive production costs. To solve these obstacles, in vivo CAR-M cell engineering with the advantages such as cost-effective, simple manufacturing is gradually coming into the field of vision of researchers and will become a prominent approach in cancer therapy.

Fig.1 Various generation structures of CAR-Ms. (Wang, 2022)

Our In Vivo CAR-M Cell Engineering Service

To overcome these challenges, Creative Biolabs has successfully established a cost-effective and simple in vivo CAR-M cell engineering platform. Since macrophages are naturally resistant to viral vectors, we used a variety of modified and optimized vectors to assist in vivo CAR-M cell engineering. Additionally, due to the strong tumor invasion of macrophages, and the ability of macrophages to process and present antigens to T cells, which will activate adaptive immunity, it will be of great help to in vivo CAR-M engineering. Leverage by years of experience, we offer comprehensive customized optimized in vivo CAR-M cell engineering service to empower global customers' diverse projects.

Fig.2 CAR-M-based tumor treatments. (Chen, 2021)

Application Prospect

What the Data Displayed

Representative data 1: One clinical study using CAR macrophages to target HER2-expressing solid tumors has shown encouraging anti-tumor effectiveness in preclinical investigations.

Fig.3 Current status of CAR macrophage studies. (Pan, 2022)

Representative data 2: In vivo CAR-M generation was generated using the MPEI/pDNA nano-complex, and its efficacy against solid tumors demonstrated that in vivo CAR expression applies to immune cells other than T cells.

Fig.4 CAR-Ms are programmed in vivo via nanocomplex-mediated gene delivery. (Shin, 2023)

Partner with Creative Biolabs

We make available an inquiry as follows that paves the way for further in-depth conversations with us.

Partner with Creative Biolabs

At the same time, we provide the following related services:

If you are interested in our in vivo CAR-M cell engineering service, please contact us or send an inquiry for more information.

Frequently Asked Questions

Q: What are the advantages of CAR-M compared to CAR-T therapy?

A: Compared with CARTs, CAR-Ms do not need a special antigen recognition mechanism to play a phagocytic effect to eliminate tumor cells, and macrophages are more invasive to solid tumors, all of which are conducive to playing a role in solid tumor elimination.

References

Wang S, et al. CAR-macrophage: An extensive immune enhancer to fight cancer. EBioMedicine. 2022, 76:103873.
Chen Y, et al. CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021, 139:111605.
Pan K, et al. CAR race to cancer immunotherapy: from CAR-T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022, 41(1):119.
Shin S, et al. Nanoparticle-based chimeric antigen receptor therapy for cancer immunotherapy. Tissue Eng Regen Med. 2023, 20(3):371-387.